The Peripheral T-Cell Lymphomas. Группа авторов

15 Gamma–Delta T‐cell Lymphomas Introduction Epidemiology and Risk Factors Biology of Primary Cutaneous Gamma–Delta T‐cell Lymphoma Must Reads References 16 Enteropathy‐Associated and Monomorphic Epitheliotropic Intestinal T‐cell Lymphomas Introduction Enteropathy‐associated T‐cell Lymphoma Refractory Celiac Disease Monomorphic Epitheliotropic Intestinal T‐Cell Lymphoma Must Reads References 17 Hepatosplenic T‐cell Lymphomas Epidemiology and Disease Incidence Basic Principles of Disease Biology Clinical Features Management of Disease in the Front Line Management of the Relapsed or Refractory Disease Splenectomy Future Directions Funding Must Reads References 18 Cutaneous T‐cell Lymphoma Introduction Epidemiology and Risk Factors Basic Principles of Disease Biology Clinical, Pathologic, and Immunophenotypic Findings Management of Front‐Line Mycosis Fungoides/Sézary Syndrome Management of Relapsed or Refractory Disease with Mycosis Fungoides/Sézary Syndrome Front‐Line Management of Non‐mycosis Fungoides Cutaneous T‐cell Lymphomas Management of Relapsed or Refractory Non‐mycosis Fungoides Cutaneous T‐cell Lymphomas Future Directions Must Reads References 19 Other Rare Subtypes of Peripheral T‐cell Lymphoma Introduction Chronic Lymphoproliferative Disorders of Natural Killer Cells Epstein–Barr Virus‐associated T‐cell and NK‐cell Lymphoproliferative Disorders of Childhood Future Directions Must Reads References

      9  Part IV: Treatment of the PTCL 20 Standard Front‐line Therapies Introduction Initial Workup and Risk Stratification Front‐line Therapy Must Reads References 21 Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin Introduction Challenges in Developing New Drugs in Peripheral T‐cell Lymphomas Drugs Approved by the US Food and Drug Administration with an Indication in Relapsed/Refractory Peripheral T‐cell Lymphoma Drugs Approved by the US Food and Drug Administration But Without An Indication in Relapsed/Refractory Peripheral T‐cell Lymphoma Drugs Approved by International Regulatory Agencies, Not Including the United States, that Carry an Indication in Relapsed/Refractory Peripheral T‐cell Lymphoma Conclusion Must Reads References 22 The Role of Autologous Stem‐cell Transplantation in Peripheral T‐cell Lymphomas Introduction Autologous Stem‐cell Transplantation in First Complete Remission Autologous Stem‐cell Transplantation in Relapsed/Refractory Disease Interpretation of Available Literature Identifying the Most Relevant Determinants for Survival among Patients with Peripheral T‐cell Lymphoma Undergoing Autologous Stem‐cell Transplantation Status of Response Prior to Autologous Stem‐cell Transplantation Risk of Stage Number of Prior Therapies and Refractory Disease Autologous Stem‐cell Transplantation on Specific Subtypes of Peripheral T‐cell Lymphoma Must reads